Abstract
Unrelated umbilical cord blood (UCB) is one of ideal hematopoietic stem cell (HSC) source for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in treatment of hematologic malignancies. Because of lack of donor and cannot use the traditional donor lymphocyte infusion (DLI) treatment, once the patients occurred recurrence of primary disease after unrelated umbilical cord blood transplantation (UCBT), their treatment for recurrence of primary disease is very limited. In this paper, authors will review the treatment strategies for recurrence of primary disease after UCBT in patients with hematologic malignancies. Key words: Unrelated donors; Cord blood stem cell transplantation; Hematologic neoplasms; Recurrence
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
